Changes in a specific type of sugarlike molecule, or glycan, on the surface of cancer cells help them to spread into other tissues, according to researchers at the University of California, Davis. Published March 23 in Proceedings of the National Academy of Sciences, the work could lead to diagnostic tests and new therapies to slow or stop the spread of cancers.
The research team led by Professor Carlito Lebrilla, UC Davis Department of Chemistry, worked with cells derived from a human cholangiocarcinoma, or bile duct cancer. Cholangiocarcinoma is relatively rare but becoming more common in the U.S. It metastasizes readily and is often incurable by the time of diagnosis.
Generally, researchers have studied how cancer cells spread by looking at the proteins on their surface membranes. Some of these proteins may serve as receptors that engage with other cells, allowing cancerous cells to attach and move into tissues.
But proteins on living cells are also coated with a wide variety of sugarlike carbohydrate molecules called glycans. These glycans modify how proteins -- and therefore the cells -- interact with their environment. While DNA dictates the protein's structure, glycans and carbohydrates are made and metabolized by the protein's own machinery. That makes studying these molecules even more challenging.
Lebrilla's laboratory at UC Davis has been studying glycans, glycoproteins and the roles they play in the body for many years, developing new techniques to analyze and characterize them.
How glycans modify proteins
Metastatic cholangiocarcinoma cells had high levels of the glycan mannose on surface proteins, Lebrilla's team discovered. These cancer cells lacked the gene for an enzyme that breaks down mannose. The presence of mannose was associated with cancer cells being able to spread out on a dish and migrate through pores in a membrane, simulating squeezing through the wall of a blood vessel into surrounding tissue.
"What is interesting here is that it's a new way to look at cancer metastasis. Instead of looking at proteins, we've looked at how protein modifications are affecting the metastatic behavior of cancer cells," Lebrilla said.
If modified glycans are a characteristic of metastatic cancers, that could present a new way to diagnose cancer and perhaps predict which cancers are likely to become invasive. The glycans and the metabolic pathways that make them could also be targets for new drugs.
Co-authors on the paper are: Diane Dayoung Park, Gege Xu and Qiongyu Li, UC Davis Department of Chemistry; Chatchai Phoomak, Worachart Lert-Itthiporn and Sopit Wongkham, Khon Kaen University, Thailand; Laura Olney, Khiem Tran, Nathan Haigh, Michiko Shimoda and Emanual Maverakis, Department of Dermatology, UC Davis School of Medicine; Simon Park, Beth Israel Deaconess Medical Center, Harvard Medical School; Beth Guillaume Luxardi and Nobuyuki Matoba, University of Louisville School of Medicine; and Fernando Fierro, Department of Cell Biology and Human Anatomy, UC Davis School of Medicine. The work was partly supported by grants from the NIH and NSF.
Lebrilla is a co-founder and member of the Scientific Advisory Board for Intervenn, a startup company developing a serum-based test for cancer.